DRA Pakistan: Rapid Alert on Falsified Propylene Glycol
The Drug Regulatory Authority of Pakistan (DRAP) issued a Rapid Alert on 22 August 2024 regarding counterfeit batches of Propylene Glycol. The batches are tagged with Dow Chemical labels, and some are declared to be from 'Dow Europe GmbH, Made in Germany'.
DRAP received the information from Dow Chemical's subsidiary in Singapore and the responsible WHO's safety unit. The warning refers to three batches, two allegedly from Dow Europe GmbH (Made in Germany) and one from The Dow Chemical Company. The labels are counterfeit and the quality and safety of the material cannot be guaranteed, according to DRAP. DRAP therefore calls on companies not to use these batches to manufacture medicines.
Companies that have used these batches should have their retained samples analysed immediately. If the samples are contaminated, the affected products should be recalled. In addition, raw materials should be screened before use and finished products should be specifically tested for contamination. More detailed information on the affected batches, including photos of the falsified containers, can be found here.
Meanwhile, the contaminated raw materials have been secured, and an investigation has been initiated. This announcement is the latest in a series of warnings from DRAP regarding propylene glycol in Pakistan.
Source:
Meet the GMP Compliance Adviser
The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.
The demo access is non-binding and ends automatically.
You may also be interested in the following articles:
